Clinical Trial

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Study acronym: EASE SBS 3
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 2, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is an extension trial to EASE SBS 2. The study looks at whether glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment. Participants in this trial will receive glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.) for approximately 2 years.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-05-05; most recent amendment 2026-01-29.
Status change: Enrolling by Invitation → Active, Not Recruiting 2026-01-29
Status change: Not Yet Recruiting → Enrolling by Invitation 2021-06-25
Trial Details
NCT Number NCT04881825
Lead Sponsor Zealand Pharma
Conditions Short Bowel Syndrome
Enrollment 129 participants
Start Date 2021-06-16
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-02